Achillion Pharmaceuticals (NASDAQ:ACHN) Stock Rating Lowered by ValuEngine

Achillion Pharmaceuticals (NASDAQ:ACHN) was downgraded by investment analysts at ValuEngine from a “sell” rating to a “strong sell” rating in a research note issued on Thursday, ValuEngine reports.

ACHN has been the subject of several other reports. BidaskClub raised Achillion Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Saturday, October 5th. Zacks Investment Research downgraded Achillion Pharmaceuticals from a “hold” rating to a “sell” rating and set a $4.75 price objective for the company. in a research note on Tuesday, August 27th. Four analysts have rated the stock with a sell rating and one has given a buy rating to the company. The company presently has an average rating of “Sell” and an average price target of $3.63.

Shares of NASDAQ ACHN opened at $3.63 on Thursday. Achillion Pharmaceuticals has a 12 month low of $1.29 and a 12 month high of $5.03. The company has a market cap of $507.09 million, a price-to-earnings ratio of -7.12 and a beta of 1.57. The business has a fifty day simple moving average of $4.00 and a 200-day simple moving average of $3.40.

Achillion Pharmaceuticals (NASDAQ:ACHN) last announced its earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.14) EPS for the quarter, meeting the consensus estimate of ($0.14). Research analysts anticipate that Achillion Pharmaceuticals will post -0.59 earnings per share for the current fiscal year.

Institutional investors have recently made changes to their positions in the stock. Bank of Montreal Can purchased a new stake in Achillion Pharmaceuticals in the 2nd quarter worth about $30,000. Paloma Partners Management Co purchased a new stake in Achillion Pharmaceuticals in the 2nd quarter worth about $74,000. Jane Street Group LLC purchased a new stake in Achillion Pharmaceuticals in the 2nd quarter worth about $78,000. SG Americas Securities LLC purchased a new stake in Achillion Pharmaceuticals in the 2nd quarter worth about $97,000. Finally, Marshall Wace LLP purchased a new stake in Achillion Pharmaceuticals in the 2nd quarter worth about $100,000. 78.57% of the stock is owned by hedge funds and other institutional investors.

Achillion Pharmaceuticals Company Profile

Achillion Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small molecule drug therapies for immune system disorders. Its lead drug candidate is ACH-4471, an inhibitor of factor D that is Phase II clinical trials for patients with paroxysmal nocturnal hemoglobinuria (PNH) and C3 glomerulopathy/immune complex membranoproliferative glomerulonephritis.

Read More: Conference Calls and Individual Investors

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Achillion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit